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AT present, inhaled glucocorticoids are widely
accepted as the therapy of choice in chronic
asthma. Treatment with inhaled glucocorticoids
significantly suppresses local airway inflamma-
tion in asthmatics, but may also have systemic
effects, e.g. a reduction of the number of circulat-
ing hypodense eosinophils or a down-modulation
of HLA-DR antigen (Ag) expression by T lympho-
cytes in peripheral blood. However, the effect of
long-term therapy with inhaled glucocorticoids
on peripheral blood monocytes (PBM), which are
the precursors of the most numerous cell type in
the lung, the alveolar macrophage, have not yet
been evaluated. We therefore investigated the ex-
pression of various cell surface Ag on PBM from
non-smoking patients with allergic asthma who
were treated for 2.5 years with a 2-receptor
agonist plus either an inhaled glucocorticoid
(beclomethasone dipropionate, BDP) (n 4) or
an anticholinergic or placebo (n 8). We com-
pared the results with healthy volunteers (n 7).
Long-term treatment of allergic asthmatics with
inhaled BDP, but not anticholinergic or placebo
therapy, was associated with a significantly lower
CDllb Ag expression (p < 0.04) and higher ex-
pression of CD13, CD14 and CD18 Ag (p < 0.05,
p < 0.02 and p < 0.04, respectively) when com-
pared with the healthy control subjects (n 7).
Most interestingly, PBM of asthmatics treated with
inhaled BDP expressed an almost two-fold higher
level of CD14 Ag on their cell surface than PBM of
patients treated with anticholinergic or placebo
(p < 0.03). No significant differences in the ex-
pression of CD16, CD23, CD25, CD32 and CD64
Ag or HLA-DR were observed between PBM from
the different patient groups or healthy controls.
Taken together, this study shows that long-term
local therapy with inhaled BDP coincides with an
altered expression of at least one cell surface Ag
on PBM from allergic asthmatics.
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Introduction
One of the major histopathological findings in
asthma is chronic inflammation of the airways.
In bronchial mucosal biopsies, this inflammation
is characterized by an accumulation of mono-
nuclear phagocYlte, eosinophils, mast cells and
T lymphocytes.- These inflammatory cells
have also been described in the bronchoalveolar
lavage fluid,
5-7 which, in addition, has been
shown to contain elevated levels of various
inflammatory mediators.7’8 It is generally be-
lieved that the airway inflammation in asthma
results from the concerted actions of the differ-
ent types of inflammatory cells and their prod-
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ucts, and underlies some of the clinical
1,3,5 symptoms.
The most numerous cell type in both the
normal and asthmatic lung is the alveolar
macrophage. This cell type is nowadays known
to play a central role in initiating, perpetuating,
ro 9 i2 and reducing inflammatory p cesses.
Monocytes and macrophages recovered from
bronchoalveolar lavage fluid of asthmatics are
highly activated,13-15 manifested in the release
of a large variety of mediators which in turn
modulate the inflammatory responses of eosino-
phils, mast cells and T cells.7’1 Furthermore, it
has been reported that alveolar macrophages of
asthmatic patients express elevated levels of
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low affinity receptors for IgE (CD23),
17 which
are capable of inducing cellular activation in
response to specific allergen.
At present, glucocorticoids are the most
effective therapy for controlling airway inflam-
mation and clinical symptoms in chronic asth-
ma.18’19 The precise mechanisms by which
glucocorticoids reduce airway inflammation are
not yet fully understood, but it is known that
they modulate gene expression by binding to
specific glucocorticoid-responsive elements in
DNA.221 One of the major mechanisms by
which glucocorticoids inhibit inflammation is
direct suppression of cytokine production by
mononuclear phagocytes and T cells
22 or the
induction of anti-inflammatory proteins such as
lipocortin-1.23 Additionally, glucocorticoids inhi-
bit the production of pro-inflammatory media-
tors indirectly by suppressing the activity of
several enzymes involved in the production of
these mediators.
Therapy with inhaled glucocorticoids for 1-4
months results in a significant decrease in the
numbers of macrophages, eosinophils, mast
cells, and T cells in the bronchial epithelium
2- 27 and submucosa of asthmatic patients. Only
mild systemic effects have been reported with a
daily dose of 1 000-2 000/g of inhaled gluco-
corticoids. Numbers of peripheral blood eosino-
phils have been shown to be reduced after
treatment with inhaled glucocorticoids.9’28 The
effect of long-term treatment with inhaled
glucocorticoids on peripheral blood monocytes
(PBM), the precursors of alveolar macrophages,
has not yet been evaluated. Identification of the
effects of therapy with inhaled glucocorticoids
on peripheral blood cells may be important, as
increased numbers of eosinophils and activated
T cells are detected in blood of asthmatic
Table 1. Patient characteristics
patients, in addition to the infiltration of inflam-
matory cells in the airways.29’3
In this report, we analysed the expression of
various cell surface Ag by PBM of non-smoking
patients with allergic asthma who were treated
for 2.5 years with an inhaled 2-receptor agonist
plus either inhaled beclomethasone dipropio-
nate (BDP), or an anticholinergic or placebo.
The patients were participants in the Dutch
double-blind placebo-controlled CNSLD
study.31’32 Our data demonstrate that PBM of
asthmatic patients treated with inhaled BDP, in
contrast to PBM of patients treated with anti-
cholinergic or placebo, show significant
changes in the expression of CDllb, CD13,
CD14 and CD18 Ag when compared with
healthy control subjects. Importantly, PBM of
asthmatics treated with inhaled BDP expressed
significantly more CD14 Ag on their cell surface
than PBM of patients who were treated with
bronchodilator or placebo. These findings sug-
gest that local inhaled glucocorticoid therapy, in
addition to earlier reported effects on blood
eosinophils,19’28 may result in systemic effects
on PBM.
Materials and Methods
Subjects
Twelve non-smoking allergic asthmatic patients
(participating in the Dutch double-blind place-
bo-controlled CNSLD study)
1,32 and seven
healthy volunteers were studied. The character-
istics of each patient are described in Table 1.
The diagnosis of asthma was made according to
the criteria of the American Thoracic Society
and was based on a history of attacks of breath-
lessness and wheezing without chronic cough
Patient Gender Age Baseline FEV1
number (years) (% of predicted)
After 2.5 years Baseline PC2o After 2.5 years
FEV1 (mg/ml) PC2o (mg/ml)
(% of predicted)
Glucocorticoid group
M 36 46.3
2 F 44 75.0
3 F 45 49.2
4 F 60 59.7
Median 44.5 54.5
Anticholinergic/placebo group
F 41 54.3
2 M 42 48.7
3 M 24 61.5
4 M 44 63.5
5 M 50 65.1
6 M 57 81.6
7 F 38 57.0
8 M 26 90.0
Median 41.5 62,5
64.5 0.13 1.46
88.5 0.06 0.45
69.6 0.05 0.21
90.3 0.06 0.96
79.1 0.06 0.71
53.1 0.03 0.04
56.5 0.24 0.87
54.7 0.19 0.58
66.3 0.02 0.05
62.7 0.28 0.18
42.3 0.14 0.04
43.6 0.13 0.06
61.5 0.13 0.02
55.6 0.14 0.06
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or sputum production. Chronic was defined as
more than three months per year. At entry to
the study, all patients showed a 20% decrease in
FEV1 resulting from inhalation of a provocative
concentration of histamine of < 8 mg/ml
(PC20).32’34 Allergy was defined as at least two
positive wheal and flare reactions to skin prick
tests with twelve common aeroallergens, or a
positive test to house dust mite.2 All patients
but one had a baseline reversibility > 10% of
predicted (one patient had a reversibility of
4%). Control subjects (three male, median age
27 years; four female, median age 23 years)
were healthy volunteers, taking no medication,
who had no history of allergy or asthma and
had negative skin prick tests. Approval for the
study protocol was obtained from the Medical
Ethics Committees of the participating centres.
All subjects gave written informed consent.
Study design
Details of the study design have been described
previously.2 Briefly, after a double-blind rando-
mization patients were treated with the 2-
receptor agonist terbutaline (two puffs of
250 pg q.i.d.) plus either: (A) inhaled glucocorti-
coid BDP, two puffs of 100 g q.i.d., (B) anti-
cholinergic bronchodilator (ipratropium bro-
mide), two puffs of 20 pg q.i.d., or (C) placebo
q.i.d. At the end of the study, no significant
differences with regard to FEV1 and PC20 were
found between the groups receiving either
ipratropium bromide or placebo. Therefore, the
data of these groups were pooled for analysis as
one single group (designated as anticholinergic/
placebo group). Heparinized venous blood of
patients was collected after completing 2.5
years of treatment. Heparinized blood of healthy
volunteers served as control.
Isolation of peripheral blood
mononuclear cells
Mononuclear cells from heparinized venous
blood were isolated by Ficoll density centrifuga-
tion (Ficoll Paque; density 1.077 g/ml; Pharma-
cia, Uppsala, Sweden) for 15 min at room
temperature (centrifugal force 1 000 X g). Peri-
pheral blood mononuclear cells (PBMC) were
washed twice at 4C using PBS (300 mosmol;
pH 7.8) supplemented with 0.5% heat-inacti-
vated BSA (Organon Teknika; Turnhout, Bel-
gium) and 0.05% w/v NaN3 (PBS/BSA/NaN3).
The cell concentration was adjusted to 5
106 cells/ml.
Immunofluorescence staining
MoAb used in this study are listed in Table 2.
CDll and CD18 moAb were used because of
the central role of leukocyte adhesion mole-
cules in the recruitment of blood cells to
inflammatory sites.5 Cell surface aminopepti-
dase-N can be recognized by CD13 moAb, and
may play a role in the inactivation of some
Table 2. Monoclonal antibodies used in this study
moAb Clone (isotype) Source
CD3 Leu-4 (IgG1) BD
CD4 Leu-3a (IgG) BD
CD8 Leu-2a (IgG) BD
CD11b 44 (IgG) Dr N. Hogg
CD13 Q20 (IgG2a) Dr C. E. van der Schoot
CD14 UCHM1 (IgG2a) Dr N. Hogg
CD15 VIM-D5 (IgM) Dr W. Knapp
CD16 Leu-1 lb (IgM) BD
CD18 LFA-1/1 (IgG1) CLB, Amsterdam, the Netherlands
CD20 B1 (IgG2a) Coulter Clone, Hialeah, FL
CD23 T(il (IgG1) Biotest, Dreieick, Germany
CD25 IL-2R (IgG1) BD
CD32 IV.3 (IgG2b) Medarex Inc., West Lebanon, NH
CD64 32.2 (IgG1) Medarex Inc.
HLA-DR L243 (IgG2a) BD
Anti-macrophage Ag RFD9 (IgG1) Dr L. W. Poulter
Isotype control (IgG) BD
Isotype control (IgG2a) BD
CD1 Leu-6 (IgG2b) BD
aBecton Dickinson, Sunnyvale, CA, USA.
bLondon, UK.
CCLB, Amsterdam, the Netherlands.
dVienna, Austria.
eRoyal Free Hospital School of Medicine, London, UK.
fUsed as IgG2b isotype control.
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inflammatory mediators.36’37 CD14 moAb was
used because it recognizes the receptor for LPS
binding protein, which may determine the
cellular responsiveness to bacterial products.
8
moAb recognizing Fc, receptors (CD16, CD32,
CD64) were used because these receptors play
a role in the response of cells to specific
antigens.39 The presence of low affinity recep-
tors for IgE, recognized by CD23 moAb, may
lead to activation of cells in response to specific
allergens.
4 Both the expression of the {,-chain
of the IL-2 receptor (CD25) and HLA-DR are
markers of cellular activation.27 RFD9 recog-
nizes a cell membrane determinant present on
alveolar macrophages, but virtually absent on
blood monocy4t4aes, and may be used as a marker
of maturation. Irrelevant isotype-matched anti-
bodies were used as controls. Reagents were
diluted to optimal concentration in PBS/BSA/
NAN,. All incubations (30 min each) were car-
ried out on ice. Each incubation was followed
by two washes with PBS/BSA/NaN3 at 4C. For
single-colour stainings, aliquots of 2.5x 105
PBMC (in a volume of 50 bl) were first incu-
bated with 50 tl moAb, washed, and subse-
quently incubated with FITC-conjugated goat
anti-mouse Ig (GAM-FITC; CLB, Amsterdam, the
Netherlands). After the last washing procedure,
the cells were resuspended in PBS/BSA/NaN.
For two-colour stainings, 50 btl PBMC were incu-
bated with both a FITC-conjugated and PE-
conjugated moAb, washed and eventually resus-
pended in FACSFLOWTM (Becton Dickinson,
Sunnyvale, CA, USA).
Flow cytometry
Flow cytometric analyses were performed using
a FACScan flow cytometer (Becton Dickinson)
equipped with a 488 nm argon laser. Residual
erythrocytes, dead cells and debris were ex-
cluded from analysis by electronic gating on the
basis of forward and perpendicular light scatter.
At least 7 500 events were acquired. Cell surface
fluorescence was analysed after setting scatter
gates on either the monocyte or lymphocyte
fraction. Within the monocyte gate, cell surface
fluorescence was expressed as molecules
equivalent to soluble FITC (MESF). MESF values
(X 104) were obtained by interpolating cell sur-
face fluorescence to a standard curve prepared
using microspheres of known fluorescence
intensities (Flow Cytometry Standards, Research
Triangle Park, NC, USA). MESF values were
corrected for background fluorescence by sub-
tracting the MESF values obtained with isotype-
matched control antibodies. Within the lympho-
cyte gate, results were expressed as the per-
centage of positively stained cells relative to an
isotype-matched control antibody. Subpopula-
tions of T lymphocytes were identified by two-
colour labelling.
Statistical analysis
Differences between groups in either the per-
centage of positively stained lymphocytes or the
level of cell surface fluorescence by monocytes
were compared using the two-tailed Mann-
Whitney U-test. Differences associated with p
values < 0.05 were regarded as statistically
significant.
Results
Long-term treatment with inhaled
BDP in asthma is associated with
differences in the level of cell surface
Ag expression by PBM
The expression of various cell surface Ag by
PBM from both non-smoking allergic asthmatics
treated for 2.5 years with either inhaled BDP or
anticholinergic/placebo, and healthy volunteers
is summarized in Table 3. PBM from patients
who received anticholinergic/placebo did not
show any significant alterations in the levels of
cell surface Ag expression when compared with
PBM from healthy controls. In contrast, PBM
from patients treated with inhaled BDP differed
significantly in the level of expression of CD 1 lb
(p < 0.04), CD13 (p < 0.05), CD14 (p < 0.02),
and CD18 (p < .0.04) Ag when compared with
PBM from healthy controls (Fig. 1). A reduced
level of CDllb Ag expression was observed,
whereas the expression of CD13, CD14, and
CD18 Ag was higher. The only significant
difference between the two groups of asthmatic
patients concerned the level of CD14 Ag ex-
pression; PBM from patients who had received
inhaled BDP expressed significantly higher le-
vels of CD14 Ag than PBM from asthmatic
patients who had received anticholinergic/pla-
cebo (Table 3, Fig. 1). Both groups of patients
and the control group, however, did not differ
in the relative numbers of CD14+ monocytes in
peripheral blood (data not shown). The expres-
sion of RDF9 by PBM of asthmatics treated with
inhaled BDP was significantly increased when
compared with PBM of healthy controls
(p < 0.01). However, this specific cell surface
fluorescence fell within two-fold the fluores-
cence intensity of an isotype-matched control
moAb, suggesting that monocytes express negli-
gible levels of RFD9 Ag. No differences in the
expression of CD16 (Fc,RIII), CD23 (FceRII),
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Table 3. Specific cell surface fluorescence by peripheral blood monocytes
Control group Anticholinergic/placebo group
(n-7) (n=8)
Glucocorticoid group (n- 4)
PBMC
% CD15+ 0.7 (0.5-2..0) 1.8 (0.4-5.5) 1.6 (0.5-6.8)
Monocytes
CD11b 19.2 (9.6-27.1)a,b 12.6 (2.1-26.4) 7.6 (4.1-13.0)c(p<4)
CD13 5.3 (1.5-6.4) 5.4 (3.6-12.9) 8.2 (6.1-18.7)c(p<5)
CD14 13.0 (9.4-18.7) 11.9 (7.9-19.7) 20.4 (13.7-21.5)c(p<’02)d(p<’3)
CD16 1.1 (0.6-2.3) 0.9 (0.6-1.6) 1.3 (0.7-1.6)
CD18 8.5 (5.7-11.0) 13.8 (6.3-33.4) 12.5 (8.8-16.1)c(p<.4)
CD23 1.0 (0.9-1.6) 1.1 (0.5-2.2) 1.3 (0.7-1.8)
CD25 0.9 (0.7-1.3) 0.9 (0.5-1.3) 1.1 (0.6-1.6)
CD32 11.7 (6.6-15.0) 13.4 (7.2-19.9) 14.0 (11.5-17.6)
CD64 7.7 (4.3-10.4) 8.4 (4.2-12.4) 7.0 (6.3-10.8)
RFD9 1.3 (0.9-1.4) 1.4 (0.6-2.4) 1.8 (1.7-2.0)c(p<.l)
HLA-DR 5.9 (3.8-6.6) 6.8 (4.8-21.4) 7.0 (5.7-9.3)
aMedian values (range).
bMESF values, corrected for background fluorescence by isotype-matched control Ab, were calculated using a calibration line obtained with
microspheres of known fluorescence intensities. Statistical analysis was performed using the two-tailed Mann-Whitney U-test.
cSignificantly different from control group.
dSignificantly different from anticholinergic/placebo group.
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FIG. 1. Expression of CD11b, CD13, CD14 and CD18 cell surface Ag (expressed as MESF xl04) by PBM. Median values are
represented as a horizontal dash (--). *Value of glucocorticoid group (3) differs significantly from control group (1). **Value
of glucocorticoid group (3) differs significantly from anticholinergic/placebo group (2).
CD25 (IL-2R), CD32 (Fc,RII) and CD64 (FcTRI)
were observed between both groups of patients
and healthy controls. The expression of CD16,
CD23, and CD25 Ag fell within two-fold the
background fluorescence of isotype-matched
control moAb, comparable with the expression
of RFD9 Ag.
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Long-term therapy with inhaled BDP
and differences in subsets of
peripheral blood lymphocytes
In addition to analysing the cell surface Ag
expression on PBM, we investigated whether
long-term therapy with inhaled BDP is asso-Cell surface antigen expression byperipheral blood monocytes in asthma
ciated with differences in the percentage of T
and B lymphocytes in peripheral blood (Table
4). No differences were observed in the percen-
tages of either CD4+ or CD8+ T cells. However,
both groups of patients had higher percentages
of HLA-DR/ T cells in their peripheral blood
than healthy controls. Treatment with inhaled
BDP did not alter the percentage of these
activated T cells. Interestingly, patients who
received anticholinergic/placebo, but not the
patients treated with inhaled BDP, had a signifi-
cantly higher percentage of B lymphocytes
(CD20+ cells) in their peripheral blood com-
pared with healthy controls (Table 4).
Discussion
In this study, we show an almost two-fold
higher expression of CD14 Ag on PBM from
allergic asthmatics treated for 2.5 years with an
inhaled glucocorticoid (BDP, 800 tg daily) com-
pared with patients treated with anticholinergic
or placebo. In addition, long-term treatment of
asthmatic patients with an inhaled glucocorti-
coid, but not anticholinergic or placebo, was
associated with a significantly reduced expres-
sion of CD1 lb Ag on PBM, and a significantly
increased expression of CD 13, CD 14, and CD18
Ag compared with healthy control subjects.
Glucocorticoids were introduced in 1949 as a
new and promising drug in the treatment of
inflammatory diseases.42 Shortly thereafter,, local
administration of glucocorticoids was com-
menced to by-pass the unwanted systemic side
effects.43 Nowadays, inhaled glucocorticoids are
widely accepted as the treatment of choice in
chronic asthma.
28 Several reports showed that
inhaled glucocorticoids are safe and almost free
of systemic effects. However, high doses of
inhaled glucocorticoids may still influence the
hypothalamus-pituitary-adrenal axis.2s’44 More
evidence for systemic effects of inhaled gluco-
corticoids comes from studies on circulating
eosinophils and T cells. Circulating hypodense
eosinophils, which have been shown to exhibit
a great inflammatory potential, were reduced in
asthmatic subjects after short-term, treatment
with inhaled glucocorticoids.45’46 Furthermore, a
small but significant reduction in HLA-DR ex-
pression by peripheral blood T cells has been
reported after 6 weeks of therapy with inhaled
glucocorticoids.
27 To our knowledge, modula-
tion of PBM by inhaled glucocorticoids has not
been described up till now.
Leukocyte adhesion molecules, among which
the CD11/CD18 family of 2 integrins, play an
important role in the recruitment of cells from
peripheral blood to the site of inflammation as
well as in other immunological and inflamma-
tory processes that require direct cellular inter-
actions.35’47’48 Both the expression and function
of adhesion molecules are augmented in re-
sponse to inflammatory mediators and cyto-
kines.49 The reduction in CD1 lb Ag expression
by PBM observed here in asthmatic subjects
treated with inhaled glucocorticoid, may have
indirectly resulted from the local glucocorticoid-
mediated reduction in inflammatory mediators
in the lung. Alternatively, systemically absorbed
BDP may be directly responsible for the modula-
tion of CD1 lb Ag expression. In contrast to a
reduced expression of CDllb, a slightly but
significantly elevated CD18 Ag expression was
seen on PBM of asthmatics treated with inhaled
glucocorticoid when compared with PBM of
healthy control subjects. The CD18 Ag is found
on the cell surface in association with one of
three different chains, i.e. the CD 1 l a, CD 1 lb,
or CDllc Ag.47 Since the expression of CDlla
and CD1 lc Ag were not analysed in this study,
we do not know whether the observed increase
in CD18 Ag expression coincides with an in-
creased expression of CD11a and/or CD 11c Ag.
Long-term treatment of asthmatics with in-
haled BDP was associated with an increased
expression of CD13 Ag by PBM compared with
healthy controls. CD13 Ag, a cell membrane-
bound aminopeptidase-N, has been shown to
play an important role in modulating the
activity of regulatory oligopeptides.6 An in-
Table 4. Lymphocyte subpopulations in peripheral blood
Control group
(n=7)
Anticholinergic/placebo
group (n= 8)
Glucocorticoid group
(n---4)
Lymphocytes
% CD20+ 4.2 (3.1-9.1) 7.2 (3.5-10.1)b(p<4) 7.6 (3.9-16.4)
% CD3/ 67.4 (57.1-82.2) 68.3 (52.6-81.9) 73.5 (53.4-79.0)
% CD3+/CD4+ 34.5 (22.0-44.1) 40.6 (29.1-53.9) 38.0 (32.1-40.9)
% CD3+/CD8+ 23.8 (16.3-30.2) 21.2 (11.3-35.7) 33.0 (13.9-42.7)
% CD3+/HLA-DR+ 1.0 (0.4-2.1) 2.0 (1.2-9.3)b(p<003) 5.6 (2.0-8.8)b(p<002)
Ratio CD4/CD8 1.6 (0.7-2.1) 1.7 (0.8-3.6) 1.2 (0.8-2.6)
aMedian values (range).
bSignificantly different from control group.
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crease in CD13 Ag expression may therefore
enhance the cell’s capacity to inactivate harmful
inflammatory peptides. In this context, it is
noteworthy that CD13 Ag expression by puri-
fied PBM increases upon in vitro culture in the
presence of IL-4, suggesting that this cytokine,
like glucocorticoids, has potential anti-inflamma-
tory effects.7’5 Future studies are needed to
determine whether the increased expression of
CD13 Ag observed here is accompanied by an
increased aminopeptidase-N activity.
The CD14 Ag expression by PBM of patients
treated with inhaled glucocorticoid was sig-
nificantl increased compared with PBM of pa-
tients who received anticholinergic/placebo and
healthy control subjects. It has been shown that
CD14 Ag can function as a receptor for LPS.38
In addition, a role for CD14 Ag has been
implicated in the adhesion of monocytes to
cytokine-activated endothelial cells.51 CD14 Ag
expression decreases upon differentiation/
maturation of monocytes into alveolar macro-
phages. This process can be inhibited by
glucocorticoids.41,52 Therefore, it may be that in
this study the interference of inhaled BDP with
the maturation of PBM manifests itself in the
increase of CD14 Ag expression.
In this study, we also show that all asthmatic
patients, treated with either inhaled glucocorti-
coid or anticholinergic/placebo, have signifi-
cantly increased percentages of HLA-DR+ T cells
in their peripheral blood when compared with
healthy control subjects. Long-term treatment
with inhaled BDP did not reduce the percentage
of circulating activated (HLA-DR+) T lympho-
cytes in both groups of patients. Recently,
Wilson et al.27 showed in an uncontrolled study
that patients treated for 6 weeks with inhaled
BDP showed a reduction in the percentage of
activated T cells. Compared with our study,
they used a higher dose of BDP and they did
not compare their result with patients who did
not receive inhaled glucocorticoids. In the
present study, we also observed that patients
treated with bronchodilator/placebo, but not
the patients treated with inhaled BDP, had a
higher percentage of B lymphocytes in peri-
pheral blood compared with healthy controls.
Therefore, treatment with inhaled glucocorti-
cold may have influenced the proportion of
circulating B lymphocytes in our group of
patients.
In summary, our data demonstrate that long-
term therapy with an inhaled glucocorticoid
coincides with an altered expression of at least
one cell surface Ag on PBM of allergic asth-
matics. In the treatment of patients clinicians
should be aware of these systemic effects of
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inhaled glucocorticoids. Future studies are
needed to determine whether changes in cell
surface Ag expression by PBM are part of the
anti-inflammatory action of inhaled glucocorti-
coids, and whether they correlate with the
glucocorticoid-induced improvement in FEV1,
PC20 and clinical symptoms.
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